Oncofetal Fibronectin mRNA in Thyroid Carcinomas
Author Information
Author(s): T Takanol, F Matsuzuka, A Miyauchi, T Yokozawa, G Liu, S Morita, K Kuma, N Amino
Primary Institution: Osaka University Medical School
Hypothesis
The expression of oncofetal fibronectin mRNA can be a target for gene diagnosis and therapy in thyroid cancer.
Conclusion
Oncofetal fibronectin mRNA is abundantly expressed in all observed cancer cells of thyroid papillary and anaplastic carcinomas, but not in normal thyroid tissues.
Supporting Evidence
- Oncofetal fibronectin mRNA was found in all six papillary carcinomas and one anaplastic carcinoma.
- Normal thyroid tissues and other benign conditions showed no expression of oncofetal fibronectin mRNA.
- The study used in situ hybridization to confirm the expression of oncofetal fibronectin mRNA.
Takeaway
This study found that a specific type of mRNA, which is usually found in cancer cells, is present in thyroid cancer but not in normal thyroid tissue, helping doctors diagnose cancer better.
Methodology
In situ hybridization was used to measure the expression of oncofetal fibronectin mRNA in various thyroid tissues.
Limitations
The study only examined a limited number of tissue types and may not represent all thyroid cancers.
Participant Demographics
The study included tissues from patients with various thyroid conditions, including normal thyroid, Graves' disease, and different types of thyroid carcinoma.
Want to read the original?
Access the complete publication on the publisher's website